Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer

Table 2 Surgical procedures and postoperative complications by the treatment interval between secondary cytoreductive surgery and adjuvant chemotherapy

	Entire cohort (n = 79)	Group 1 (treatment interval ≤ 10 days, n = 42)	Group 2 (treatment interval > 10 days, n = 37)	p value
Surgical procedures
Tumorectomy	57 (72.2%)	31 (73.8%)	26 (70.3%)	0.726
LN^a dissection	20 (25.3%)	10 (23.8%)	10 (27.0%)	0.743
Bowel surgery	20 (25.3%)	13 (31.0%)	7 (18.9%)	0.220
Bladder/ureter injury	6 (7.6%)	2 (4.8%)	4 (10.8%)	0.311
Vessel injury	2 (2.5%)	2 (4.8%)	0 (0.0%)	0.179
Upper abdomen^b	13 (16.5%)	9 (21.4%)	4 (10.8%)	0.204
Lung surgery	3 (3.8%)	2 (4.8%)	1 (2.7%)	0.633
Postoperative complications^c				0.406
I	5 (6.3%)	3 (7.1%)	2 (5.4%)
II	9 (11.4%)	6 (14.3%)	3 (8.1%)
III (IIIa, IIIb)	2 (2.5%)	2 (4.8%)	0 (0.0%)
IV, V	0 (0.0%)	0 (0.0%)	0 (0.0%)

^aLN Lymph node;
^bUpper abdomen surgery included splenectomy, pancreatectomy, and hepatectomy
^cPostoperative complications were classified into ‘Clavien-Dindo classification’

ISSN: 1757-2215